Pfizer Inc. (NYSE:PFE) Shares Bought by Breakwater Capital Group

Breakwater Capital Group boosted its position in Pfizer Inc. (NYSE:PFE) by 4.3% in the 1st quarter, HoldingsChannel reports. The firm owned 76,325 shares of the biopharmaceutical company’s stock after purchasing an additional 3,144 shares during the period. Breakwater Capital Group’s holdings in Pfizer were worth $1,934,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the company. Mcdonald Partners LLC increased its stake in Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after acquiring an additional 9,963 shares during the last quarter. Bank of Jackson Hole Trust purchased a new stake in Pfizer during the 4th quarter worth $264,000. Harvey Capital Management Inc. purchased a new position in Pfizer in the fourth quarter valued at about $544,000. ING Groep NV grew its position in shares of Pfizer by 48.6% during the fourth quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company’s stock worth $26,881,000 after buying an additional 331,403 shares in the last quarter. Finally, WCM Investment Management LLC increased its position in shares of Pfizer by 128.7% in the 4th quarter. WCM Investment Management LLC now owns 115,913 shares of the biopharmaceutical company’s stock worth $3,062,000 after purchasing an additional 65,238 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $23.42 on Thursday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a 50-day simple moving average of $23.02 and a 200 day simple moving average of $25.02. The company has a market capitalization of $133.15 billion, a PE ratio of 16.61, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the business earned $0.82 earnings per share. The firm’s quarterly revenue was down 7.8% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.34%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Analysts Set New Price Targets

Several research firms have weighed in on PFE. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.